Oppenheimer Remains Bullish on Integra LifeSciences (IART) After Traveling with Management

October 4, 2016 9:01 AM EDT
Get Alerts IART Hot Sheet
Price: $78.56 --0%

Rating Summary:
    13 Buy, 9 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 21 | New: 6
Trade IART Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Oppenheimer reiterated an Outperform rating and $93.00 price target on Integra LifeSciences (NASDAQ: IART) after traveling with management.

Analyst Steven Lichtman commented, "We recently traveled with IART in a series of investor meetings. Our focus for IART over the past number of years has been the out-sized operating margin expansion opportunity. While we certainly see continued leverage ahead, we believe IART is also adding sustainable solid top-line growth to the story. The company has accelerated both R&D and sales & marketing investment over the past couple of years while leveraging COGS and G&A. We believe this will lead to a consistent cadence of pipeline products and sustainable mid-to-upper single digit organic sales growth. Two opportunities in particular that we focused on during our time on the road—IART’s ability to cross-sell product lines to hospitals and the runway ahead to grow the highmargin regenerative business."

For an analyst ratings summary and ratings history on Integra LifeSciences click here. For more ratings news on Integra LifeSciences click here.

Shares of Integra LifeSciences closed at $83.13 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Add Your Comment